Duke Bahn
University of Southern California
37 Papers
237 Citations
Duke Bahn is an academic researcher from University of Southern California. The author has contributed to research in topics: Prostate cancer & Cryoablation. The author has an hindex of 14, co-authored 31 publications. Previous affiliations of Duke Bahn include Memorial Hospital of South Bend & University of Rochester.
Chat about Author
Papers
Focal prostate cryoablation: initial results show cancer control and potency preservation.
TL;DR: Focal cryoablation can provide biochemical and local control of prostate cancer while preserving potency and continence and is recommended for patients whose prostate cancer is believed to be unilateral.
184
Salvage Cryosurgery for Recurrent Prostate Cancer After Radiation Therapy: A Seven-Year Follow-up
Duke Bahn,Fred T. Lee,Paul Silverman,Eric D. Bahn,Robert A. Badalament,Anil Kumar,Jeffrey Greski,John C. Rewcastle +7 more
TL;DR: Improved survival rates and no known latent complications indicate cryosurgery is a promising form of treatment for radiation-resistant prostate cancer.
132
Salvage focal and salvage total cryoablation for locally recurrent prostate cancer after primary radiation therapy.
Andre Luis de Castro Abreu,Duke Bahn,Duke Bahn,Scott Leslie,Sunao Shoji,Paul Silverman,Mihir M. Desai,Inderbir S. Gill,Osamu Ukimura +8 more
TL;DR: To present the oncological and functional outcomes of salvage focal (SFC) and salvage total (STC) cryoablation for recurrent prostate cancer (PCa) after failed primary radiotherapy.
100
Prostate cancer: US-guided percutaneous cryoablation. Work in progress.
TL;DR: These preliminary results demonstrate that cryosurgery can cause necrosis of prostate cancer and it is necessary to determine if this means longer disease-free intervals and increased patient survival compared with results of current therapeutic methods.
90
Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006.
David G. Bostwick,David J. Waters,Edward R. Farley,Isabelle Meiers,Daniel B. Rukstalis,William A. Cavanaugh,Haakon Ragde,Martin Dineen,Duke Bahn,Stephen Scionti,Richard Babian,David S. Ellis,John C. Rewcastle,Harry B. Burke,Gerald L. Andriole,Gary Onik,Al E. Barqawi,John A. Maksem,Winston E. Barzell +18 more
TL;DR: The group evaluated 4 specific pathologic features that may influence his treatment decision regarding the natural istory of prostate cancer, multifocality, cancer volme, and accuracy of cancer detection by current ethods.
82